3-FEA: Difference between revisions
>Unity added approval tag |
>Unity Grammatics |
||
Line 6: | Line 6: | ||
| ''[[3-FEA/Summary|Summary sheet: 3-FEA]]'' | | ''[[3-FEA/Summary|Summary sheet: 3-FEA]]'' | ||
|} | |} | ||
'''3-Fluoroethamphetamine''' (also known as '''3-FEA''') is a novel synthetic ring-substituted fluorinated [[chemical class::amphetamine]] compound that produces [[psychoactive class::entactogen]]ic and [[psychoactive class::stimulant]] effects when [[Routes of administration|administered]]. 3-FEA is structurally related to a series of [[designer drug|designer]] fluorinated [[substituted amphetamine]]s that originally included compounds such as [[2-FA]], [[2-FMA]], [[3-FA]], [[4-FMA]], [[4-FA]]<ref>Quednow, B., Girreser, U., Junge, T., & Ro, P. (2005). Isomeric Fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs), 148, 143–156. https://doi.org/10.1016/j.forsciint.2004.05.003</ref> | '''3-Fluoroethamphetamine''' (also known as '''3-FEA''') is a novel synthetic ring-substituted fluorinated [[chemical class::amphetamine]] compound that produces [[psychoactive class::entactogen]]ic and [[psychoactive class::stimulant]] effects when [[Routes of administration|administered]]. 3-FEA is structurally related to a series of [[designer drug|designer]] fluorinated [[substituted amphetamine]]s that originally included compounds such as [[2-FA]], [[2-FMA]], [[3-FA]], [[4-FMA]], [[4-FA]].<ref>Quednow, B., Girreser, U., Junge, T., & Ro, P. (2005). Isomeric Fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs), 148, 143–156. https://doi.org/10.1016/j.forsciint.2004.05.003</ref> | ||
Like its parent compound [[3-FA]], the pharmacological, toxicological, and subjective effects of 3-FEA in humans have yet to be mapped out in detail. Early reports have so far characterized 3-FEA as a moderately potent [[serotonin]]-dominant triple [[monoamine]] [[releaser]] (or triple [[reuptake inhibitor]]) that produces a unique balance of [[entactogen]]ic and [[stimulant]] effects that skews more to the hedonic-euphoric side (like one of its popular predecessor [[4-FA]]), than towards the functional and productive (e.g. as [[2-FA]] or [[2-FMA]] are considered to be). | Like its parent compound [[3-FA]], the pharmacological, toxicological, and subjective effects of 3-FEA in humans have yet to be mapped out in detail. Early reports have so far characterized 3-FEA as a moderately potent [[serotonin]]-dominant triple [[monoamine]] [[releaser]] (or triple [[reuptake inhibitor]]) that produces a unique balance of [[entactogen]]ic and [[stimulant]] effects that skews more to the hedonic-euphoric side (like one of its popular predecessor [[4-FA]]), than towards the functional and productive (e.g. as [[2-FA]] or [[2-FMA]] are considered to be). |